Overview
Serious Pneumonia and Critical Pneumonia caused by the 2019-nCOV infection greatly threats patients' life, UC-MSCs treatment has been proved to play a role in curing multiple diseases. And this study is conducted to find out whether or not it will function in 2019-nCOV infection Pneumonia.
Description
Serious Pneumonia and Critical Pneumonia caused by the 2019-nCOV infection greatly threats patients' life, UC-MSCs treatment has been proved to play a role in curing multiple diseases. And this study is conducted to find out whether or not it will function in 2019-nCOV infection Pneumonia. And we are going to get the permission of the enrolled patients. Besides the present clinical treatment, UC-MSCs treatment will be applied to those fulfilling the enrollment. After a period of UC-MSCs treatment, the analysis of UC-MSCs treatment will be completed from related aspects.
Eligibility
Inclusion Criteria:
- 18-80 years old ,no gender restriction
- According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV infection(Trial Version 6), patients are diagnosed with severe or critical 2019-nCoV pneumonia
- Women of childbearing age should have a negative blood pregnancy test before the start of dosing and agree to take effective contraceptive measures during the trial until the last follow-up (28 days)
- Previous detection of Nucleotide or antibody of 2019-nCoV pneumonia was positive
- Voluntarily participate in this clinical study and sign a written informed consent. If the patient cannot obtain informed consent, he can authorize his legal representative.
Exclusion Criteria:
- Liver SOFA score of more than 3 points;
- HIV positive
- Highly allergic constitution or history of severe allergies;
- Pregnant and lactating women;
- Patients with malignant tumors;
- Patients with previous history of pulmonary embolism;
- Participating in clinical trials of other drugs within 3 months before enrollment.
- be thought by researchers to be inappropriate to participate in this clinical study.